NICE REVIEW OF CANCER DRUGS FOR THE TREATMENT OF CHRONIC MYELOID LEUKAEMIA

Early day motion 1831, tabled 18 May 2011 by Alan Meale (Labour). Signed by 43 members.

That this House is alarmed that the National Institute for Health and Clinical Excellence (NICE) announced in its recent Appraisal Consultation document reviewing the use of the drugs Dasatinib, Nilotinib and high dose Imatinib for patients suffering from resistant chronic myeloid leukaemia (CML) that NICE had decided not to recommend NHS prescription of these life-saving cancer drugs for the treatment of this condition; is aware that currently more than 700 people in the UK discoverannuallythey have CML, and that currently more than 3,000 people are living with it; notes recent clinical evidence has established that patients benefiting from these drugs who show continued positive response from their use are likely to establish a normal average life expectancy the same as that experienced by most of the nation's population; and calls on the Government to act immediately to ensure chronic leukaemia sufferers acquire these drugs to deal with their health condition.

Signatures by party: Labour 27, Liberal Democrat 5, DUP 4, Conservative 2, Plaid Cymru 2, Alliance 1, Independent 1, Social Democratic and Labour Party 1.